BioAtla (BCAB) Competitors $0.45 -0.01 (-3.05%) As of 02:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCAB vs. THTX, CTNM, KYTX, EXOZ, ATOS, IVVD, BHST, PROC, SGMT, and IOBTShould you be buying BioAtla stock or one of its competitors? The main competitors of BioAtla include Theratechnologies (THTX), Contineum Therapeutics (CTNM), Kyverna Therapeutics (KYTX), Exozymes (EXOZ), Atossa Therapeutics (ATOS), Invivyd (IVVD), BioHarvest Sciences (BHST), Procaps Group (PROC), Sagimet Biosciences (SGMT), and IO Biotech (IOBT). These companies are all part of the "pharmaceutical products" industry. BioAtla vs. Its Competitors Theratechnologies Contineum Therapeutics Kyverna Therapeutics Exozymes Atossa Therapeutics Invivyd BioHarvest Sciences Procaps Group Sagimet Biosciences IO Biotech Theratechnologies (NASDAQ:THTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Do insiders and institutionals hold more shares of THTX or BCAB? 77.2% of BioAtla shares are held by institutional investors. 11.5% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, THTX or BCAB? Theratechnologies has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Does the media refer more to THTX or BCAB? In the previous week, BioAtla had 1 more articles in the media than Theratechnologies. MarketBeat recorded 2 mentions for BioAtla and 1 mentions for Theratechnologies. Theratechnologies' average media sentiment score of 1.87 beat BioAtla's score of 0.94 indicating that Theratechnologies is being referred to more favorably in the media. Company Overall Sentiment Theratechnologies Very Positive BioAtla Positive Does the MarketBeat Community prefer THTX or BCAB? Theratechnologies received 6 more outperform votes than BioAtla when rated by MarketBeat users. However, 64.10% of users gave BioAtla an outperform vote while only 54.39% of users gave Theratechnologies an outperform vote. CompanyUnderperformOutperformTheratechnologiesOutperform Votes3154.39% Underperform Votes2645.61% BioAtlaOutperform Votes2564.10% Underperform Votes1435.90% Do analysts prefer THTX or BCAB? BioAtla has a consensus target price of $5.00, suggesting a potential upside of 1,014.83%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 4.00BioAtla 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better earnings & valuation, THTX or BCAB? Theratechnologies has higher revenue and earnings than BioAtla. Theratechnologies is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$88.67M1.33-$23.96M-$0.08-32.00BioAtla$11M2.38-$123.46M-$1.22-0.37 Is THTX or BCAB more profitable? BioAtla has a net margin of 0.00% compared to Theratechnologies' net margin of -3.75%. Theratechnologies' return on equity of 0.00% beat BioAtla's return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-3.75% N/A -4.31% BioAtla N/A -187.30%-96.33% SummaryBioAtla beats Theratechnologies on 10 of the 19 factors compared between the two stocks. Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAB vs. The Competition Export to ExcelMetricBioAtlaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$26.20M$3.11B$5.60B$8.62BDividend YieldN/A1.57%5.28%4.18%P/E Ratio-0.2633.1427.2520.00Price / Sales2.38468.68413.35158.30Price / CashN/A168.6838.2534.64Price / Book0.313.437.124.70Net Income-$123.46M-$72.35M$3.24B$248.14M7 Day Performance-1.80%7.30%2.71%2.48%1 Month Performance3.77%17.78%8.93%6.15%1 Year Performance-71.61%-16.89%31.30%13.59% BioAtla Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCABBioAtla2.8262 of 5 stars$0.45-3.0%$5.00+1,014.8%-71.4%$26.20M$11M-0.2660Gap DownTHTXTheratechnologiesN/A$2.59-2.3%N/A+107.3%$119.09M$88.67M-25.90140Positive NewsCTNMContineum Therapeutics2.571 of 5 stars$4.43+21.0%$22.50+407.9%-71.3%$114.61M$50M-2.2531Positive NewsGap UpKYTXKyverna Therapeutics2.2135 of 5 stars$2.65+3.9%$18.50+598.1%-74.7%$114.53M$7.03M-0.7896Gap DownEXOZExozymesN/A$13.50+0.7%N/AN/A$112.97MN/A0.0029News CoverageGap DownATOSAtossa Therapeutics1.6401 of 5 stars$0.87+11.5%$7.13+722.0%-29.2%$111.97MN/A-3.948IVVDInvivyd3.8169 of 5 stars$0.93-0.5%$5.85+529.0%-46.4%$111.56M$36.69M-0.47100Positive NewsGap DownBHSTBioHarvest SciencesN/A$6.75+7.8%$13.67+102.5%N/A$110.87M$27.70M-5.40N/APositive NewsPROCProcaps GroupN/A$0.95-40.3%N/A-62.7%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeSGMTSagimet Biosciences2.3745 of 5 stars$3.49-1.7%$22.40+541.8%+24.8%$107.06M$2M-1.988News CoverageIOBTIO Biotech4.0512 of 5 stars$1.62+14.1%$9.33+476.1%+13.6%$106.73MN/A-1.1830Positive NewsShort Interest ↓Gap UpHigh Trading Volume Related Companies and Tools Related Companies THTX Alternatives CTNM Alternatives KYTX Alternatives EXOZ Alternatives ATOS Alternatives IVVD Alternatives BHST Alternatives PROC Alternatives SGMT Alternatives IOBT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCAB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAB Stock Free BCAB Stock Alerts